News und Analysen
![Royal Gold to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on Tuesday, December 14: https://mms.businesswire.com/media/20191106005902/en/190143/5/Royal_Gold_Logo_-_no_shadow_-_Mar_07.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXNsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d67b61076d94be393538149881101cfcf4f8cab/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Royal_Gold_Logo_-_no_shadow_-_Mar_07.jpg?locale=de)
Royal Gold to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on Tuesday, December 14
Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold” or the “Company,” “we” or “our”) announced today that management will present at the Virtual Non-Deal Roadshow series
![Eutelsat Wins "strategic Transaction of the Year” Award for Its Investment in OneWeb: https://mms.businesswire.com/media/20191112005524/en/397236/5/Eutelsat_Communications_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGJwRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--30ceaf00bf58adb5af52f7e64a9750ca6f8d4b65/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Eutelsat_Communications_logo.jpg?locale=de)
Eutelsat Wins "strategic Transaction of the Year” Award for Its Investment in OneWeb
Regulatory News:
Eutelsat communications (Euronext Paris: ETL) is delighted to receive the "Strategic Transaction of the Year” award at this year's World Satellite Business Week in recognition of
DGAP-News: GEA Group Aktiengesellschaft: A Capital Market Information
DGAP-News: GEA Group Aktiengesellschaft: Eine Kapitalmartkinformation
![Eurofins Technologies bringt den neuen Lateral-Flow-Reader RapidScan ST5-W - die einzige für mehrere Lebensmittel- und Umweltschnelltests verifizierte Plattform - auf den Markt : https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=de)
Eurofins Technologies bringt den neuen Lateral-Flow-Reader RapidScan ST5-W - die einzige für mehrere Lebensmittel- und Umweltschnelltests verifizierte Plattform - auf den Markt
Eurofins Technologies (Paris:ERF), ein Anbieter von Testkits und Systemen für Laboranalysen, gibt die Markteinführung seines neuen Lateral-Flow-Readers RapidScan ST5-W bekannt, der speziell für
![Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=de)
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field
![Vifor Pharma comments on media speculation: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
![Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNElsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4d0ef2109eb59269aca9850381b8fb5000d84e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xencor_RGB_fullcolor.jpg?locale=de)
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
DGAP-News: MorphoSys und Incyte geben weitere 'Real World' Ergebnisse der RE-MIND2-Studie mit Tafasitamab (Monjuvi(R)) in Kombination mit Lenalidomid zur Behandlung des R/R DLBCL bekannt
DGAP-Adhoc: United Internet AG: Ralph Dommermuth prüft Angebote zu außerbörslichen Paketerwerben von Aktien an der United Internet AG
DGAP-Adhoc: United Internet AG: Ralph Dommermuth assesses offers for block acquisitions of shares in United Internet AG
![First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
![RPM to Announce Fiscal 2022 Second-Quarter Results on January 5, 2022: https://mms.businesswire.com/media/20200903005685/en/818366/5/Rust-Oleum-logo+%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXV5VEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1206ccaebe9d96bb2d59789e9bb04711aeaa0317/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Rust-Oleum-logo+-28002-29.jpg?locale=de)
RPM to Announce Fiscal 2022 Second-Quarter Results on January 5, 2022
RPM International Inc. (NYSE: RPM) announced today that it will release its financial results for the fiscal 2022 second quarter ended November 30, 2021, before the stock market opens on Wednesday
![Guidewire Announces NXT Level Technologies as New Consulting Alliance Partner: https://mms.businesswire.com/media/20200616005489/en/798643/5/pr_20200616_aspen_launch-ASPEN-FINAL-BADGE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBei8vT3c9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--59ca41c19ab90b527b0007dec2aaf96657dd0448/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pr_20200616_aspen_launch-ASPEN-FINAL-BADGE.jpg?locale=de)
Guidewire Announces NXT Level Technologies as New Consulting Alliance Partner
Guidewire (NYSE: GWRE) announced that NXT Level Technologies, an insurance IT services provider specializing in Guidewire products, has joined Guidewire PartnerConnect as a Consulting alliance
Aurubis AG: Aurubis AG und Wärme Hamburg GmbH bauen größte Industriewärmeversorgung Deutschlands weiter aus
Aurubis AG: Aurubis AG and Wärme Hamburg GmbH to further expand Germany's largest industrial heat system
![Eurofins Enhances Clinical and COVID-19 Testing Offering in Japan Through Acquisition of Genetic Lab Co.,Ltd.: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=de)
Eurofins Enhances Clinical and COVID-19 Testing Offering in Japan Through Acquisition of Genetic Lab Co.,Ltd.
Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and a leader in clinical diagnostics testing, announces a share purchase agreement with Transgenic Inc
![Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
![Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
DGAP-News: Stabilus S.A. bestätigt vorläufige Zahlen für GJ2021 und schlägt Dividende von 1,25 € je Aktie vor
DGAP-News: Stabilus S.A. confirms preliminary figures for FY2021 and proposes dividend of €1.25 per share
![Vici Properties Inc. Declares Regular Quarterly Dividend: https://mms.businesswire.com/media/20201118006119/en/840126/5/caesars+logo_highres.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXFjVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48fabea00e7f4e84dec00f04c60adf71c810e44e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/caesars+logo_highres.jpg?locale=de)
Vici Properties Inc. Declares Regular Quarterly Dividend
VICI Properties Inc. (NYSE: VICI) (“VICI Properties” or the “Company”) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.36 per share of common stock